Elimination of Osteosarcoma by Necroptosis with Graphene Oxide-Associated Anti-HER2 Antibodies

The prognosis for non-resectable or recurrent osteosarcoma (OS) remains poor. The finding that the majority of OS overexpress the protooncogene HER2 raises the possibility of using HER2 as a therapeutic target. However, clinical trials on the anti-HER2 antibody trastuzumab (TRA) in treating OS find...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Hongmei, Jensen, Peter E., Chen, Xinjian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770144/
https://www.ncbi.nlm.nih.gov/pubmed/31491952
http://dx.doi.org/10.3390/ijms20184360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770144/
https://www.ncbi.nlm.nih.gov/pubmed/31491952
http://dx.doi.org/10.3390/ijms20184360

Ejemplares similares